Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Monlunabant

INVESTIGATIONAL

Peripherally restricted cannabinoid CB1 receptor inverse agonist

2
graded results
0
ongoing records
2
effect domains
Evidence spread
High evidence 0Moderate evidence 2Low evidence 0Very low evidence 0

Monlunabant is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Obesity; Oral tablet; as of 2026-07-13. Novo Nordisk

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Monlunabant INVESTIGATIONAL
Brain and mood Mixed
Moderate evidence

CB1 CONTRAST (non-incretin landscape context): monlunabant, a CB1 inverse agonist designed to be peripherally restricted, showed dose-dependent NEUROPSYCHIATRIC...

Knop FK et al., Lancet Diabetes Endocrinol, 2025 (monlunabant phase-2a, PMID 41038215); c... Source
Full findingCB1 CONTRAST (non-incretin landscape context): monlunabant, a CB1 inverse agonist designed to be peripherally restricted, showed dose-dependent NEUROPSYCHIATRIC adverse events in its phase-2a obesity trial, against the rimonabant precedent (CB1-antagonist depression/suicidality led to withdrawal). A preclinical study found monlunabant suppresses appetite via CENTRAL CB1 receptors, suggesting it is not fully peripherally confined and may carry rimonabant-like psychiatric risk. Decision-relevant CNS-safety contrast: CB1-antagonism carries a mechanism-specific neuropsychiatric liability the incretins do not appear to share.
PopulationMonlunabant phase-2a (NCT05891834): N=242 obesity + metabolic syndrome, 16 weeks, Canada; + a male-mouse central-mechanism study.
Fundingindustry-Novo Nordisk (Inversago Pharma)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Monlunabant INVESTIGATIONAL
weight-loss Decrease
Moderate evidence

In adults with obesity and metabolic syndrome, once-daily oral monlunabant 10 mg gave 7.1 kg weight loss vs 0.7 kg placebo at 16 weeks. Higher doses (20, 50 mg) showed...

Knop et al., Lancet Diabetes Endocrinol 2025; Novo Nordisk press 2024-09-20 Source
Full findingIn adults with obesity and metabolic syndrome, once-daily oral monlunabant 10 mg gave 7.1 kg weight loss vs 0.7 kg placebo at 16 weeks. Higher doses (20, 50 mg) showed dose-dependent withdrawals driven by neuropsychiatric/GI adverse events.
PopulationPhase 2a, N=243, 16 wk, randomised double-blind placebo-controlled dose-ranging (10/20/50 mg), 25 centres Canada; adults obesity + metabolic syndrome
Fundingindustry - Novo Nordisk (disclosed; amycretin)
Comparatorsplacebo